Invadopodia: A potential target for pancreatic cancer therapy

[Display omitted] Dissemination of cancer cells is an intricate multistep process that represents the most deadly aspect of cancer. Cancer cells form F-actin-rich protrusions known as invadopodia to invade surrounding tissues, blood vessels and lymphatics. A number of studies have demonstrated the s...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2021-03, Vol.159, p.103236-103236, Article 103236
Main Authors: Luo, Yan, Hu, Jisheng, Liu, Yong, Li, Le, Li, Yilong, Sun, Bei, Kong, Rui
Format: Article
Language:English
Subjects:
Cell Line, Tumor
Extracellular Matrix
Humans
Invadopodia
Metastasis
Neoplasm Invasiveness
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Podosomes
Therapeutic targets
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Dissemination of cancer cells is an intricate multistep process that represents the most deadly aspect of cancer. Cancer cells form F-actin-rich protrusions known as invadopodia to invade surrounding tissues, blood vessels and lymphatics. A number of studies have demonstrated the significant roles of invadopodia in cancer. Therefore, the specific cells and molecules involved in invadopodia activity can provide as therapeutic targets. In this review, we included a thorough overview of studies in invadopodia and discussed their functions in cancer metastasis. We then presented the specific cells and molecules involved in invadopodia activity in pancreatic cancer and analyzed their suitability to be effective therapeutic targets. Currently, drugs targeting invadopodia and relevant clinical trials are negligible. Here, we highlighted the significance of potential drugs and discussed future obstacles in implementing clinical trials. This review presents a new perspective on invadopodia-induced pancreatic cancer metastasis and may prosper the development of targeted therapeutics against pancreatic cancer.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2021.103236